TQB-3525 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData, Phase II drugs for Metastatic Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TQB-3525’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TQB-3525 is under development for the treatment of metastatic advanced endometrial cancer, cervical cancer, ovarian cancer, relapsed and refractory mantle cell lymphoma, relapsed and refractory diffuse large B-cell lymphoma, non-small cell lung cancer, advanced solid tumors, relapsed/refractory peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and relapsed and refractory follicular lymphoma. It acts by targeting isoforms of phosphoinositide 3-kinase (PI3K alpha/delta).
The drug candidate is formulated as tablet administered through oral route.
It was also under development for the treatment of human epidermal growth factor receptor 2 negative breast cancer and relapsed, refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Chia Tai Tianqing Pharmaceutical Group overview
Chia Tai Tianqing Pharmaceutical Group (CTTQ) manufactures and commercializes anticancer drugs. The company produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, engineering novel liver, cardiovascular, cancer, mental, anesthesia, urinary, and others. The company operates through its technology and research and development centers in Jiangsu. CTTQ is headquartered in Lianyungang, Nanjing, China.
For a complete picture of TQB-3525’s drug-specific PTSR and LoA scores, buy the report here.